Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-04-06 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
详式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report." It details the changes in share ownership among key shareholders of 特一药业集团股份有限公司, including inheritance and property division among family members. The document includes sections on the purpose of the equity change, the method of change, funding sources, future plans, impact analysis on the company, and declarations by the information disclosure obligors. It also references compliance with Chinese securities laws and regulations such as the Securities Law and the Measures for the Administration of Takeovers. The content is focused on reporting a significant change in major shareholding due to inheritance and internal family share transfers, with detailed shareholding percentages before and after the change. This matches the definition of a Major Shareholding Notification (MRQ), which involves notification of changes in significant share ownership levels crossing thresholds. The document is not an announcement of a report publication, nor is it a financial report or management report. It is a formal disclosure of a major shareholding change as required by regulatory authorities.
2022-04-06 Chinese
国浩律师（深圳）事务所关于许丹青先生、许丽芳女士因继承导致其在特一药业的权益发生变动事项的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the change in equity ownership of certain shareholders due to inheritance. It discusses the legal qualifications of the inheritors, the shareholding changes, compliance with regulatory requirements, and confirms that the change does not trigger a mandatory tender offer. The document is not a financial report, earnings release, or management discussion. It is a legal proceeding related document providing legal opinions on shareholding changes due to inheritance. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length and content confirm it is a full legal opinion, not just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2022-04-06 Chinese
关于控股股东及其一致行动人权益变动的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding changes in the equity holdings of the controlling shareholder and their concerted parties due to the death and inheritance of a key shareholder. It details the shareholding before and after the change, confirms no substantial change in control, and mentions that the share transfer procedures are ongoing. The document is titled as a "提示性公告" (prompting announcement) about equity changes and references a detailed equity change report filed elsewhere. It does not contain financial statements, audit information, or detailed financial data. It is not a full report but an announcement of a shareholding change event. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length is short (1901 characters), and it is not a report publication announcement or regulatory filing. Therefore, the correct classification is MRQ with high confidence.
2022-04-06 Chinese
2022年第一季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is a quarterly announcement regarding the convertible bonds (可转换公司债券) of the company 特一药业集团股份有限公司. It details the bond issuance, conversion price adjustments, and the bond conversion and shareholding changes for the first quarter of 2022. The document includes specific bond codes, conversion prices, regulatory approvals, and shareholding structure changes. It is not a full financial report but a specific update on convertible bond conversions and related share changes. The document length is 2716 characters, which is relatively short and focused on bond conversion details rather than comprehensive financial data. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as convertible bond conversions.
2022-04-01 Chinese
关于提前归还可转债部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the early repayment of part of the funds raised through convertible bonds temporarily used to supplement working capital. It discusses the use and repayment of raised funds, referencing previous announcements and providing updates on the status of these funds. There are no financial statements, detailed financial results, or management analysis present. The document is a formal disclosure about capital usage and repayment, which fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report, so it is not a Report Publication Announcement (RPA).
2022-03-24 Chinese
关于举行2021年度网上业绩说明会的通知
Investor Presentation Classification · 95% confidence The document is a notice about holding the 2021 annual performance explanation meeting (业绩说明会) online, scheduled for March 24, 2022. It invites investors to participate and submit questions in advance. The document does not contain any financial statements or detailed financial data, nor does it present the actual performance results. It is an announcement about an upcoming investor presentation event focused on discussing the annual performance. Therefore, it fits the category of Investor Presentation (IP) rather than an Annual Report or Earnings Release. The document length is short and it is clearly a notice for a meeting rather than the meeting materials themselves, but since it is about the performance explanation meeting, it is best classified as Investor Presentation (IP).
2022-03-21 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.